The Korean Journal of Cytopathology (대한세포병리학회지)

The Korean Society for Cytopathology (대한세포병리학회)
권호 표지

Biology and Oncogenesis of Human Papillomavirus and Its Clinical Application

인간 유두종 바이러스의 생물학적 특성과 종양발생과정에 대한 이해와 임상적 적용

  • Park, Jong-Sup (Department of Obstetrics & Gynecology, Kangnam St. Mary's Hospital, The Catholic University of Korea, College of Medicine)
  • 박종섭 (가톨릭대학교 의과대학 강남성모병원 산부인과학교실)
  • Published : 2004.05.30
Download PDF
⟨ Previous Next ⟩

Abstract

Keywords

References

  1. Pisani P, B:ay F, Parkin DM. Estimation of the worldwide prevalence of cancer for 25 sites in the adult population. Int J Cancer 2002;97:72-81 https://doi.org/10.1002/ijc.1571
  2. Bosch FX, Manos MM， Munoz N, et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International Biological Study on Cervical Cancer (IBSCC) Study Group. J Natl Cancer Inst 1995; 87:796-802 https://doi.org/10.1093/jnci/87.11.796
  3. Schiffman MH, Bauer HM, Glass AG, et al. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst 1993;85:958-64 https://doi.org/10.1093/jnci/85.12.958
  4. Brinton LA. Epidemiology of cervical cancer overview. The epidemiology of human papillomavirus and cervical cancer. eds. Munoz N, Bosch FX, Shah KV, Meheus A. IARC Scientific Pulblications. Lyon, 1992
  5. Lorincz AT. Reid R, Jensen AB, Greenberg MD, Lancaster W, Kurman RJ. Human papillomavirus infection of the cervix: relative risk association of 5 common anogenital types. Obstet Gynecol 1992;79:328-37
  6. De Villiers EM. Heterogeneity of the human papillomavirus group. J Virol 1989;63:4898-903
  7. Walker J, Bloss JD, Liao SY, Berman M, Bergen S, Wilczynski SP. Human papillomavirus genotypes as a prognostic indicator in carcinoma of uterine cervix. Obstet Gynecol 1989;74:781-5
  8. Ho GYF, Bjrk RD, Klein S, et al. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst 1995;87:1365-71 https://doi.org/10.1093/jnci/87.18.1365
  9. Remmink AJ, Walboomers JMM, Helmerhorst TJM, et a1. The presenee of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: natural history up to 36 months. Int J Cancer 1995; 61:306-1 1 https://doi.org/10.1002/ijc.2910610305
  10. Kim CJ, Jeong JK, Park MS, et al. HPV oligonucleotide microarray-based detection of HPV geno types in cervical neoplastic lesions. Gynecol Oncol 2003;89:21-7
  11. Hudson JB, Bedell M, McCance DJ, Laimins LA. Immor-talization and altered differentiation of human keratinocytes in vitro by the E6 and E7 open reading frames of human papillomavirus type 18. J Viral 1990;64:519-26
  12. Munger K, Phelps WC, Bobb V, Howley PM, Schlegel R. The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J Virol 1989;63:4417-21
  13. Scheffner M, Huibregtse JM, Vierstra RD, Howley PM. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 1993;75:495-505 https://doi.org/10.1016/0092-8674(93)90384-3
  14. Arroyo M, Bagchi S, Raychaudhuri P. Association of the human papillomavirus type 16 E7 protein with the S-phase-specific E2F-cyclin A complex. Mol Cell Biol 1993;13:6537-46 https://doi.org/10.1128/MCB.13.10.6537
  15. Klaes R, Friedrich T, Spitkovsky D, et al. Overexpression of p16 INK4a as specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer 2001;92:276-84 https://doi.org/10.1002/ijc.1174
  16. Doeberitz MK. New molecular tools for efficient screening of cervical cancer. Dis Markers 2001;17:123-8 https://doi.org/10.1155/2001/249506
  17. Cullen AP, Reid R, Campion M, Lorincz AT. Analysis of the physical state of different human papillomavirus DNAs in intraepithelia1 and invasive neoplasm. J Viral 1991;65: 606-12
  18. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nature 2002;2:342-50
  19. Park JS, Kim EJ, Lee JY, Sin HS, Namkoong SE, Um SJ. Functional inactivation of p73, a homolog of p53 tumor suppressor protein, by human papillomavirus E6 proteins. Int J Cancer 2001;91:822-7 https://doi.org/10.1002/1097-0215(200002)9999:9999<::AID-IJC1130>3.0.CO;2-0
  20. Hopfl R, Heim K, Christensen N, et al. Spontaneous regression of CIN and delayed hypersensitivity to HPV-16 oncoprotein E7. Lancet 2000;356:1985-6 https://doi.org/10.1016/S0140-6736(00)03315-8
  21. Park JS, Kim EJ, Kwon HJ, Hwang ES, Namkoong SE, Um SJ. Inactivation of interferon regulatory factor-1 tumor suppressor protein by HPV E7 oncoprotein. Implication for the E7-mediated immune evasion mechanism in cervical carcinogenesis. J Biol Chem 2000;275:6764-9 https://doi.org/10.1074/jbc.275.10.6764
  22. Cullen TS. Cancer of the Uterus, London, Kimpton. 1900
  23. Galvin GA, Jones HW, TeLinde RW. Clinical relationship of carcinoma in situ and invasive carcinoma of the uterine cervix. J Am Med Assos 1952;149:744-8 https://doi.org/10.1001/jama.1952.02930250026009
  24. Papanicolaou GN. A survey of the actualities and poten-tialities of exfoliative cytology in cancer diagnosis. Ann Med 1968;30:661-74
  25. Reagan JW, Seidemann IL, Saracusa Y. The cellular morphology of carcinoma in situ and dysplasia or atypical hyperplasia of the uterine cervix. Cancer 1953;6:224-35 https://doi.org/10.1002/1097-0142(195303)6:2<224::AID-CNCR2820060203>3.0.CO;2-H
  26. Committee for Histological Definitions. Editorial. Acta Cytol 1962;6:235-7
  27. Richart RM. Natural history of cervical intraepithelial neoplasia. Clin Obstet Gynecol 1968;10:748-84 https://doi.org/10.1097/00003081-196712000-00002
  28. National Cancer Institute Workshop. The 1988 Bethesda system for reporting cervical/vaginal cytologic diagnosis. JAMA 1989;262:931-4 https://doi.org/10.1001/jama.262.7.931
  29. The National Cancer Institute Workshop. The Bethesda system for reporting cervical/vaginal cytology diagnoses. Acta Cytol 1993;37:115-24
  30. Kurman RJ, Henson DE, Herbst A, Noller KL, Schiffman MH. Interim guidelines for management of abnormal cervical cytology. JAMA 1994;271: 1866-9 https://doi.org/10.1001/jama.271.23.1866
  31. Solomon D, Davey D, Kurman RJ, et al. The 2001 Bethesda System. Terminology for reporting results of cervical cytology. JAMA 2002;287:2114-9 https://doi.org/10.1001/jama.287.16.2114
  32. Wright TC Jr, Cox JT, Massad LS, Twiggs LB, Wilkinson EJ, ASCCP-sponsored Consensus Conference. 2001 Con-sensus guidelines for the management of wornen with cervical cytological abnormalities. JAMA 2002;287:2120-9 https://doi.org/10.1001/jama.287.16.2120
  33. The ASCUS-LSIL Triage Study (ALTS) Group. A randomiz-ed rial on the management of low-grade squamous intra-epithelial lesion cytology interpretations. Am J Obstet Gynecol 2003;188:1393-400 https://doi.org/10.1016/S0002-9378(03)00413-7
  34. The ASCUS-LSIL Triage Study (ALTS) Group. Results of a randomized trial on the management of cytology inter-pretations of atypical squamous cells of undetermined significance. Am J Obstet Gynecol 2003; 188: 1383-92 https://doi.org/10.1016/S0002-9378(03)00418-6
  35. Bolick D, Hellman DJ. Laboratory implementation and efficacy assessment of ThinPrep cervical cancer screening system. Acta Cytol 1998;42:209-13 https://doi.org/10.1159/000331548
  36. McQuarrie HG, Ogden J, Costa M. Understanding the financial impact of covering new screening technology: the case of automatic Pap smears. J Reprod Med 2000;45:898-906
  37. Solomon D. Role of triage testing in cervical cancer screening. J Natl Cancer Inst Monogr 2003;31:97-101
  38. Richart RM, Wright TC Jr. Controversies in the management of low-grade cervical intraepithelial neoplasia. Cancer 1993;71: 1413-21 https://doi.org/10.1002/cncr.2820710406
  39. Raab SS. Human papillomavirus reporting; impact on Bethesda cytology report. Arch Pathol Lab Med 2003; 127:969-72
  40. American Society of Cytopathology. Cervical cancer cyto-logy practice guidelines. Acta Cytol 2001;45:201-26 https://doi.org/10.1159/000327278
  41. Solomon D, Schiffman M, Tarone R. ALTS Study group. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst 2001;93:293-9
  42. Nobbenhuis M, Walboomers JMM, Helmerhorst TJM, et al. Relation of human papillomavirus to cervical lesions and consequences for cervical cancer screening: a prospective study. Lancet 1999;354:20-5 https://doi.org/10.1016/S0140-6736(98)12490-X
  43. Cuzick J, Beverley E, Ho L, et al. HPV testing in primary screening of older women. Br J Cancer 1999;81 :554-8 https://doi.org/10.1038/sj.bjc.6690730
  44. Schiffman MH, Herrero R, Hildesheim A, et al. HPV testing in cervical cancer screening; results from women in a high-risk province of Costa Rica. JAMA 2000;283:87-93 https://doi.org/10.1001/jama.283.1.87
  45. Shlay JC, Dunn T, Byers T, Baron AE, Douglas JM Jr. Prediction of cervical intraepithelial neoplasia grade 2-3 using risk assessment and human papillomavirus testing in women with atypia on Papanicolaou smears. Obstet Gynecol 2000;96:410-6 https://doi.org/10.1016/S0029-7844(00)00907-8
  46. Mandelblatt JS, Lawrence WF, Womak SM, et al. Benefits and costs of using HPV testing to screen for cervical cancer. JAMA 2002;287:2372-81 https://doi.org/10.1001/jama.287.18.2372
  47. Wallin KL, Wiklund F, Angstrom T, et al. Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. N Engl J Med 1993;341: 1633-38